相关实验视频

Updated: Jan 10, 2026

Surgical Models of Gastroesophageal Reflux with Mice

Surgical Models of Gastroesophageal Reflux with Mice

Published on: August 25, 2015

帕纳克斯notoginseng-Bletilla条纹通过调节NLRP3炎症体和p38 MAPK通路来改善反流食道炎症

Xin Yang^1,2, TingTing Wu¹, HuiPing Zhu¹

¹Department of Spleen and Stomach Diseases, Suzhou Hospital of Traditional Chinese Medicine, Affiliated to Nanjing University of Chinese Medicine, No.889, Wuzhong West Road, Suzhou City, 215000 Jiangsu Province China.

|November 24, 2025

概括

帕纳克斯notoginseng-Bletilla条纹 (PN-BS) 通过改善食道屏障功能,有效治疗反流性食道炎 (RE). 它抑制NLRP3炎症酶和p38 MAPK通路,在RE模型中减少炎症和粘膜损伤.

科学领域:

胃肠病学胃肠病学
药理学药理学是指药理学的学科.
分子生物学分子生物学

背景情况:

反流性食道炎 (RE) 涉及食道粘膜损伤和屏障功能障碍.
了解RE的分子机制对于开发有效的治疗方法至关重要.

研究的目的:

研究Panax notoginseng-Bletilla条纹菌 (PN-BS) 对逆流性食道炎 (RE) 的治疗作用.
阐明PN-BS在RE中的作用背后的分子机制,重点关注炎症和MAPK通路.

主要方法:

通过使用胆囊和基复合技术,建立了一种RE的老鼠模型.
通过将HET-1 A细胞暴露在胆汁盐中,创建了体外RE细胞模型.
评估了食道粘膜损伤,屏障功能,细胞活力,炎症因子和蛋白质水平 (克劳丁-4,克劳丁-5,NLRP3,分裂-酶-1,p38 MAPK).

主要成果:

在RE大鼠中,PN-BS显著减轻了食道粘膜损伤和炎症.
在大鼠和细胞模型中,PN-BS改善了食道屏障功能障碍.
PN-BS的活性成分抑制了NLRP3炎症酶和p38 MAPK通路激活,抑制剂增强了这些效应.

结论:

PN-BS通过增强食道屏障功能来证明RE的治疗潜力.
该机制涉及NLRP3炎症酶和p38 MAPK通路的抑制.
PN-BS为治疗反流性食道炎提供了一个有前途的治疗策略.

关键词:

消化道上皮质屏障消化道上皮质屏障在NLRP3炎症酶体中,NLRP3炎症酶体在P38 MAPK信号中,P38 MAPK传递信号.帕纳克斯 (Panax notoginseng) - 布莱蒂拉 (Bletilla) 条纹状的斑点是什么逆流性食道炎是什么?

更多相关视频

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation

Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation

Published on: January 10, 2025

相关概念视频

Gastroesophageal Reflux Disease II: Clinical Features and Management

Gastroesophageal Reflux Disease II: Clinical Features and Management

Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...

Gastroesophageal Reflux Disease I: Meaning and Pathophysiology

Gastroesophageal Reflux Disease I: Meaning and Pathophysiology

Gastroesophageal Reflux Disease (GERD) involves the recurrent backflow of the stomach or duodenal contents into the esophagus, leading to troublesome symptoms and potential esophageal mucosal damage. Although GERD is often referred to as a disease, it is more accurately described as a syndrome, as it encompasses a range of symptoms and complications rather than a singular pathological entity, impacting a large number of individuals as the most prevalent upper gastrointestinal problem. Roughly...

Gastritis III: Clinical Manifestations and Management

Gastritis III: Clinical Manifestations and Management

The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...

Peptic Ulcer Disease IV: Management

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...

Barrett Esophagus-II: Clinical Manifestations and Management

Barrett Esophagus-II: Clinical Manifestations and Management

Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...